Peptide

Pinealon

Pinealon (Glu-Asp-Arg, EDR)

A synthetic tripeptide derived from the pineal peptide fraction. Marketed as a CNS bioregulator. Distinct from Epitalon and Endoluten despite the shared pineal-derived origin.

Editor approved

Summary Can Pinealon improve memory or protect the brain? Show / hide ↓

Pinealon is a synthetic tripeptide, meaning a small chain of three amino acids, marketed for brain health. In laboratory studies and rat experiments, it reduced some signs of nerve-cell damage and improved movement after brain injury, but animal results do not prove it works in people. Small, non-blinded Russian studies involving older adults with mild cognitive impairment, meaning early memory problems, reported better memory and reaction times after 10-day courses of about 100 to 200 micrograms daily. These studies were not independently repeated, and there are no strong, high-quality human trials. Pinealon is also sold in combination products, but the best dose for people is unknown.

What this means for you: Pinealon has promising animal findings but weak human evidence. There is not enough reliable evidence to buy it for memory or brain protection.

weak evidence

Research snapshot No human clinical trials. Khavinson bioregulator peptide.

Updated 2026-08-11

Pinealon is a Russian peptide bioregulator claimed to support brain function. Evidence is limited to animal studies and Russian-language reports. No independent human trials exist. Its cognitive claims are not verified by international research standards.

Evidence tierTier 5, Mechanistic hypothesis, minimal human data

Typical doseCommon user protocol: 100 to 200 mcg per day (or 1 to 2 mg for Russian-format capsules), morning, 10 to 20 consecutive days, two to four cycles per year.

SafetyNo documented serious adverse events in published Russian studies. Long-term independent safety data does not exist. Not tested for pediatric use.

Categoryresearch peptide (Cytogen)

Last verified2026-08-05

Pinealon is one of the shorter and better-characterized Khavinson tripeptides. Its selling point is CNS penetration: unlike the larger Cytomax complexes, this three-residue peptide is small enough to cross the blood-brain barrier and reach neuronal targets directly.

Mechanistically, Pinealon is claimed to enter the cell nucleus and bind DNA at specific sequences, along with histone H1.3, dampening oxidative-stress responses and supporting neuronal viability. In cortical neuron cultures exposed to glutamate excitotoxicity, Pinealon has reduced apoptosis markers. In rat models of Alzheimer-like pathology (amyloid injection into the hippocampus), Pinealon preserved dendritic spine density in CA1 pyramidal neurons compared with saline controls. In traumatic brain injury models, Pinealon has reduced infarct volume and improved motor recovery.

Human data is thin but not absent. Small Russian studies in elderly subjects with mild cognitive impairment report improved memory scores and reaction time after 10-day oral cycles at doses around 100 to 200 mcg per day. These trials are not double-blind and have not been independently replicated.

The Integrative Peptides US-market product CogniPep uses Pinealon (branded as Subcortical Bioregulator AM49) alongside Cortagen (Cerebral Neuropeptide C14) and Vesugen (Neurovascular Bioregulator 33B) at low microgram doses per capsule. This is a considerably lower dose than the Russian Pinealon capsules (5000 to 10000 mcg), though whether the microgram range is sufficient or whether the milligram range is over-shooting has not been settled in a dose-finding trial.

Our position: Pinealon sits at Tier 5 for humans. Preclinical data is consistent, from one research consortium. Independent replication is thin. Users cycle it because it is short-course and reportedly well-tolerated, not because a robust human evidence base has been built.

Related in the encyclopedia

Further reading